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SQUAMOUS CELL CARCINOMA OF THE LUNG
Shibuya K, Nakajima T, Yasufuku K, Iyoda A, Suzuki M,
Sekine Y, Iizasa T, Hiroshima K.
Department of Thoracic Surgery and Pathology, Chiba,
Japan.
Eur Respir J 2006, 28 Suppl 50: 601S.
High-resolution video bronchoscopy with narrow band
imaging (HRVB-NBI) is a new endoscopic technique gradually
entering the arena of clinical research. The high resolution, in
combination with the NBI filter for the wavelengths of blue,
green, and red, allows in vivo imaging of angiogenesis.
In this study, the authors examined the micro-vessel
networks of 79 patients with abnormal sputum cytology or
lung cancer. Using this technique, they reported a mean
vessel diameter of 63.7 m for carcinoma in situ, 136.5 m
for early invasive lesions, and 259.4 m for overt squamous
cell carcinoma, respectively (p  0.029).
Editorial comment: This technique is promising to evaluate
the multi-step process of angiogenesis as a part of carcinogenesis
of the bronchus. This is of interest, as it opens possibilities for
endoscopic follow-up of dysplastic lesions in (ex-)smokers, and
perhaps early response evaluation of anti-angiogenic treatments
in patients with established lung cancer.
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The achievement of tumor clearance of mediastinal
lymph nodes (LNs) is an important prognostic element in
patients with stage IIIA-N2 non-small cell lung cancer treated
with induction therapy followed by surgery.
In this abstract, the authors reported their experience
with real-time endobronchial ultrasound-guided transbron-
chial needle aspiration (rt-EBUS-TBNA) to assess mediasti-
nal LNs in patients with IIIA-N2 NSCLC after induction
chemotherapy. A total of 143 LN stations were punctured in
83 patients with either partial response (n  44) or stable
disease (n  39) on CT (computed) scan. In 129 instances,
lymphocytes were seen in the smears. There was no verifi-
cation of positive results, and specificity and positive predic-
tive value were assumed to be 100%. For patients with
negative findings, ensuing thoracotomy was the gold standard
for comparison. Sensitivity of the technique was 70%, and
negative predictive value was not reported.
Editorial comment: Adequate assessment of response to
therapy in both the primary tumor and the mediastinal LNs, is
very important in this setting. The value of the standard tool,
CT scan, is limited, whereas FDG-PET scores better, espe-
cially for primary tumor response (Vansteenkiste J et al,
Lancet Oncol 2004, 5: 531–540). To reassess mediastinal
LNs, re-mediastinoscopy has been used in a few retrospective
series, but a recent prospective Leuven Lung Cancer Group
study with strict methodological design revealed disappoint-
ing results of re-mediastinoscopy in IIIA-N2 NSCLC patients
who already had a thorough initial mediastinoscopy (De Leyn
P et al, J Clin Oncol 2006, 24: 3333–3339). As reported by
Krasnik et al., rt-EBUS-TBNA is a very attractive alternative
for these patients that now needs further validation in pro-
spective comparator studies investigating negative predictive
values and impact on clinical management.
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Morbidity and mortality associated with pneumonec-
tomy after induction therapy have been reported by some
groups to be unacceptably high, especially in case of right-
sided pneumonectomy.
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In this analysis, the authors compared postoperative
mortality (at 30 and 90 days) and major morbidity of their
resections in the time interval 1999–2005 (group 1, 43
patients undergoing surgery after induction; group 2, 196
primary surgery). Demographic data were similar, except for
older age and more female patients in group 2. There were no
significant differences between the two groups in terms of
30-day mortality (9.3% vs 5.6%), incidence of empyema
(2.3% vs 2%), or bronchopleural fistula (2.3% vs 5.1%).
Editorial comment: Some authors have reported that pneu-
monectomy after induction treatment is universally deleteri-
ous. This article from a group with high skills in thoracic
surgery does not confirm this finding. Other prospective
series on surgical combined modality for stage IIIA-N2
NSCLC (induction chemotherapy plus surgery) documented
rewarding 5-year survival rates of approximately 30% and no
excess in postoperative mortality. In the Swiss prospective
experience (Betticher et al, J Clin Oncol 2003, 21: 1752–
1759), mortality with surgery post induction was 3% (2 of
75), a figure not exceeding standard postoperative outcome
measures. In the Leuven prospective experience with post
induction surgery, there was one postoperative death among
39 lobectomy patients, and no postoperative death among 31
pneumonectomy patients (Lorent et al, Ann Oncol 2004, 15:
1645–1653). Further research to optimize surgical combined
modality treatment for stage IIIA-N2 NSCLC is warranted.
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